Latest news articles

Added 16 days ago Drug news

RI 002 (formerly Bivigam) establishes a new PDUFA date of 2 April 2019.- ADMA Biologics, Inc

ADMA Biologics, Inc. ,a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment...

Added 27 days ago Drug news

CHMP recommends authorisation of lanadelumab for the Prevention of HAE Attacks.- Shire plc

Shire plc announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive...

Added 1 month ago Drug news

Complete Response Letter for Ruconest sBLA for expanded indication in hereditary angioedema.- Pharming.

Pharming has received a Complete Response Letter (CRL) from the FDA regarding the supplemental Biologics License Application (sBLA) for Ruconest...

Search all news articles for Immunity disorders
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria.

+ 7 more

Inflammatory Bowel Disease Knowledge Centre

Inflammatory Bowel Disease Knowledge Centre

The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.

Load more

Guidelines

ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients

This part of the European Fungal Infection Study Group (EFISG) of the European Society of Clinical Microbiology and Infectious Diseases...

Added 5 years ago

Search all guidelines for Immunity disorders
 

Journal articles

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.

In patients with primary antibody deficiencies, subcutaneous administration of IgG (SCIG) replacement is effective, safe, well-tolerated, and can be self-administered at home. A new SCIG replacement at 20% concentration (Hizentra®)...

Added 8 months ago

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment of a variety of malignant and autoimmune disorders.

Added 1 year ago

Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders

Human immunoglobulin is an established replacement therapy for patients with primary immunodeficiency disorders (PIDs). Recombinant human hyaluronidase (rHuPH20) is a...

Added 4 years ago

Search all journal articles for Immunity disorders
 
Lauren McCracken

Lauren McCracken works for our sister agency Digital Medical Communications (DMC Ltd) as an Associate Medical Writer. Lauren is very passionate about healthcare and how technology can improve treatments, and has written a blog series 'Transforming lives through technology'

... Read more

EAACI hot topics: Allergen specific immunotherapy (AIT)

When should AIT be used to treat your patients with allergies? Is it right for every allergy? And do we really know the long-term effects of this treatment? This blog highlights some of the talking points surrounding AIT discussed at this year’s EAACI Congress.